Clinical Trials - April 2, 2015
Antipsychotic Trial Results Published
Results from a multicenter study evaluating the effects of the investigational compound brexpiprazole as monotherapy in adult patients with schizophrenia recently were published online by the American Journal of Psychiatry. Brexpiprazole is an investigational psychotropic compound discovered by Otsuka Pharmaceutical, Co., Ltd. and under co-development with Lundbeck. The study, “Efficacy and Safety of Brexpiprazole for […]
Drug Development Pharma - November 27, 2014
Lundbeck Alcohol Addiction Drug Wins Approval in UK
Just two days after the Danish company’s Lundbeck CEO stepped down for an ethics lapse, the UK’s National Institute for Health and Care Excellence (NICE) gave Selincro (namelfene) approval in final draft guidance, meaning the country’s National Health Service will make funding available for the £42.42-per-14-tablet-pack medication within three months. “We are pleased to be able […]
In a new job - November 25, 2014
Lundbeck CEO Steps Down
Lundbeck CEO Ulf Wiinberg is out of a job after failing to follow procedures on stock ownership. Wiinberg accepted shares of Stratified Medical from its founder last year without permission, violating the company’s internal policies, according to Lundbeck. And it’s an “aggravating circumstance” that Lundbeck later invested about 19 million Danish kronor, equal to US$3.2 […]
Clinical Trials - June 18, 2014
Positive results from Lundbeck study
The Danish company has announced results from a connect study showing that Brintellix in adults with major depressive disorder met the primary study endpoint of demonstrating superiority versus placebo in cognivite function. The objectives of this randomized, double-blind, placebo-controlled study were to evaluate the effects of Brintellix on cognitive function using objective neuropsychological tests associated […]
Acquisition - May 8, 2014
Lundbeck acquires Chelsea Therapeutics
H. Lundbeck A/S entered into a definitive agreement under which Lundbeck will commence a tender offer to acquire Chelsea Therapeutics International, Ltd. Under the agreement, Lundbeck will gain rights to the FDA-approved product droxidopa with expected launch during 2014. Lundbeck is offering USD 658 million. The total potential consideration represents an attractive premium of 59% over the closing […]
Drug Development Pharma - March 20, 2014
Lundbeck and Otsuka initiate European launch of Abilify Maintena
The two companies has announced the launch of Abilify Maintena in Europe following approval by the European Commission in November 2013. Denmark is the first European country where Abilify Maintena is fully reimbursed and accessible to people with schizophrenia, and more than ten markets are expected to launch by the end of 2014. Abilify Maintena (aripiprazole) is […]
